Neurogenic Orthostatic Hypotension (nOH) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Neurogenic Orthostatic Hypotension (nOH) Market Outlook

Thelansis’s “Neurogenic Orthostatic Hypotension (nOH) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Neurogenic Orthostatic Hypotension (nOH) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Neurogenic Orthostatic Hypotension (nOH) Overview

Neurogenic orthostatic hypotension (nOH) is a specific form of orthostatic hypotension characterized by impaired regulation of standing blood pressure due to autonomic dysfunction. Patients with nOH assume an upright position and commonly experience dizziness, visual disturbances, presyncope, and syncope symptoms. However, many patients present with more subtle complaints, including tiredness, impaired cognitive function, weakness, fatigue, leg buckling, visual blurring, and difficulty breathing upon standing. These symptoms tend to worsen in hot weather or during fever, after heavy meals, during prolonged standing, and early in the morning. Various factors influence orthostatic hypotension. Cross-sectional analysis indicates that age, drug effects, orthostatic stress in neurological disorders (particularly Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, and autonomic neuropathies), as well as dehydration, deconditioning, and poor nutrition, contribute to the development of orthostatic hypotension in the elderly population. Two distinct patient groups with primary nOH have been identified, regardless of clinical diagnosis. Patients with evidence of cardiac noradrenergic denervation on neuroimaging demonstrate loss of noradrenergic innervation throughout the body, abnormalities in neurochemical responses to test drugs, and evidence of compensatory upregulation of adrenoceptors. On the other hand, patients with central neurodegeneration and intact cardiac noradrenergic innervation on neuroimaging exhibit neurochemical abnormalities suggesting a deficiency in central norepinephrine. They often exhibit high blood pressure (supine hypertension) that disrupts the narrow range of normal blood pressure. As a result, patients may display orthostatic hypotension and supine hypertension at different times.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Neurogenic Orthostatic Hypotension (nOH) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034